Optomed Q2: Soft Q2 sales raises the stakes for H2 recovery - Redeye
Bildkälla: Stockfoto

Optomed Q2: Soft Q2 sales raises the stakes for H2 recovery - Redeye

Redeye provides an update following Optomed’s Q2 2025 report. Sales came in below our expectations, and we had anticipated a more pronounced impact from the Aurora AEYE camera. As a result, we have made downward adjustments to our sales estimates, leading to an updated fair value range.

Redeye provides an update following Optomed’s Q2 2025 report. Sales came in below our expectations, and we had anticipated a more pronounced impact from the Aurora AEYE camera. As a result, we have made downward adjustments to our sales estimates, leading to an updated fair value range.
Börsvärldens nyhetsbrev